Vol. 5 No. 12 (2025)
Reimbursement Reviews

Abemaciclib (Verzenio)

decorative image of the issue cover

Published December 19, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Abemaciclib (Verzenio), 50 mg, 100 mg, and 150 mg oral tablets.
  • Indication: For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a GnRH agonist.